Beleaguered Cannabis Firm Tilray (TLRY) Finally Gains Momentum
Tilray (TLRY) stock jumps on strong earnings and an expanded addressable market Following a torrential implosion of market value since February last year, cannabis firm Tilray (NASDAQ:TLRY, TSE:TLRY) finally gave its stakeholders a reason to smile. Management reported encouraging developments for its fiscal year 2022, including double-digit revenue growth and expectations to be cash flow positive in FY 2023. Further, Switzerland legalizing medical marijuana theoretically expands the total addressable market for cannabis companies. Tilray in particular specializes in exploring the therapeutic p...